News
12-09-2011, 08:00 AM
Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that results from ongoing Phase II clinical trials of Puma's investigational drug PB272 (neratinib) were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium that is currently taking place in San Antonio, Texas.
More... (http://www.news-medical.net/news/20111209/Positive-results-from-Pumas-neratinib-Phase-II-trials-presented-at-CTRC-AACR-San-Antonio-Breast-Cancer-Symposium.aspx)
More... (http://www.news-medical.net/news/20111209/Positive-results-from-Pumas-neratinib-Phase-II-trials-presented-at-CTRC-AACR-San-Antonio-Breast-Cancer-Symposium.aspx)